Cargando…

Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report

BACKGROUND: Nintedanib is a multi-target receptor tyrosine kinase inhibitor. In two recent randomized phase 3 trials (INPULSIS™-1 and -2), it has been shown to slow the disease progression of idiopathic pulmonary fibrosis (IPF) by reducing the decline in the forced vital capacity (FVC). Although the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikeda, Satoshi, Sekine, Akimasa, Baba, Tomohisa, Yamakawa, Hideaki, Morita, Masato, Kitamura, Hideya, Ogura, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778330/ https://www.ncbi.nlm.nih.gov/pubmed/26940352 http://dx.doi.org/10.1186/s12890-016-0201-9

Ejemplares similares

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2019)

Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2017)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Clinical Features of Idiopathic Interstitial Pneumonia with Systemic Sclerosis-Related Autoantibody in Comparison with Interstitial Pneumonia with Systemic Sclerosis
por: Yamakawa, Hideaki, et al.
Publicado: (2016)

Incidence of acute exacerbation in patients with interstitial lung disease after COVID-19 vaccination
por: Sakayori, Masashi, et al.
Publicado: (2023)

A 16-year Follow-up Case of Interstitial Pneumonia with Systemic Sclerosis-rheumatoid Arthritis Overlap Syndrome
por: Yamakawa, Hideaki, et al.
Publicado: (2017)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
por: Yamakawa, Hideaki, et al.
Publicado: (2018)

Identification and Characteristics of Co-isolation of Multiple Nontuberculous Mycobacteria
por: Asaoka, Masato, et al.
Publicado: (2021)

Pathologically Proven Spontaneous Remission of IgG4-related Retroperitoneal Fibrosis
por: Yamakawa, Hideaki, et al.
Publicado: (2017)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
por: Takehara, Kazutaka, et al.
Publicado: (2022)

Radiological and Pathological Features of Cyst Formation in Idiopathic Multicentric Castleman Disease
por: Otoshi, Ryota, et al.
Publicado: (2023)

Patients with Terminal Interstitial Pneumonia Require Comparable or More Palliative Pharmacotherapy for Refractory Dyspnea than Patients with Terminal Lung Cancer
por: Okabayashi, Hiroko, et al.
Publicado: (2021)

Disease activity of lung cancer at the time of acute exacerbation of interstitial lung disease during cytotoxic chemotherapy
por: Sekine, Akimasa, et al.
Publicado: (2022)

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity
por: Yamanaka, Yumie, et al.
Publicado: (2017)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
por: Kaushal, Mohit, et al.
Publicado: (2022)

Suspected accelerated disease progression after discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: Two case reports
por: Okamori, Satoshi, et al.
Publicado: (2017)

Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
por: Ishida, Yuriko, et al.
Publicado: (2022)

A case of bilateral hilar and mediastinal lymphadenopathy developing during treatment for Mycobacterium avium complex
por: Yamanaka, Yumie, et al.
Publicado: (2017)

Desquamative Interstitial Pneumonia Complicated with IgG4-related Lung Disease
por: Yamakawa, Hideaki, et al.
Publicado: (2017)

Fatal diffuse alveolar haemorrhage mimicking acute exacerbation in idiopathic pulmonary fibrosis treated with nintedanib
por: Sugino, Keishi, et al.
Publicado: (2017)

Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia
por: Ikeda, Satoshi, et al.
Publicado: (2021)

Pilot Quasi-Randomized Controlled Study of Herbal Medicine Hochuekkito as an Adjunct to Conventional Treatment for Progressed Pulmonary Mycobacterium avium Complex Disease
por: Enomoto, Yasunori, et al.
Publicado: (2014)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON
por: Song, Jin Woo, et al.
Publicado: (2019)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
por: Rodríguez-Portal, José Antonio
Publicado: (2017)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
por: Imai, Ryosuke, et al.
Publicado: (2020)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil
por: Pereira, Carlos Alberto de Castro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m5f731pnm0j0snnak9jcs91cc4